Investing $24 billion to develop prototype vaccines for the 26 known viral families is a prudent and necessary expenditure. The economic and human costs of pandemic-related disruptions far exceed this amount, and being prepared with prototype vaccines could save countless lives and stabilize economies in future outbreaks.